Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Pain, Intractable 1Mucositis 1Leukemia 1Inflammatory Bowel Diseases 1Diverticulitis 1Diverticular Diseases 1Colonic Neoplasms 1Cancer Pain 1Breast Neoplasms 1Breast Cancer Female 1Breakthrough Pain 1Bone Marrow Failure Disorders 1Bites and Stings 1Anemia, Aplastic 1Agnosia 1Acute Pain 1

Interventions

Morphine 16Oxycodone 14Fentanyl 10Methadone 7nabiximols 5Lidocaine 5Acetaminophen 5resiniferatoxin 4Hydromorphone 4Ethanol 4Acupuncture Therapy 4Transcutaneous Electric Nerve Stimulation 3Buprenorphine 3Transcranial Direct Current Stimulation 2Tapentadol 2Surveys and Questionnaires 2Standard of Care 2Sodium Bicarbonate 2Radiosurgery 2Radiofrequency Ablation 2Pharmaceutical Services 2Naloxone 2Ketamine 2Electroacupuncture 2Dronabinol 2Control Groups 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1rofecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cancer Pain × Passive Cutaneous Anaphylaxis × Clear all
NCT05053308 2023-08-07

Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

Seoul National University

Phase NA Withdrawn

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡